Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00171769 · ClinicalTrials.gov registry record · Phase 3
Atrial Fibrillation Feasibility Certoparin Trial - AFFECT
A Phase 3 study of Persistent Nonvalvular Atrial Fibrillation, sponsored by Novartis.
- Completed
- Registry status
- Phase 3
- Development phase
- 200
- Enrollment target
- 2
- Study locations
NCT00171769: Completed Phase 3 study of Persistent Nonvalvular Atrial Fibrillation, sponsored by Novartis.
NCT00171769 is a Phase 3 study of Persistent Nonvalvular Atrial Fibrillation that has completed, run by Novartis. The registered enrollment target is 200 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (74% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00171769, a Phase 3 study of Persistent Nonvalvular Atrial Fibrillation, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 200 participants
- Enrollment target
- 2
- Study locations
Study Summary
This trial is designed to provide data about feasibility and safety of short-term treatment with the low-molecular-weight heparin certoparin in patients with persistent nonvalvular atrial fibrillation
Conditions Studied
Interventions
- DRUG Certoparin
Study Locations (2)
New Jersey
- Novartis Pharmaceuticals - East Hanover
Other
- - Investigative Centers
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2005-04 |
| Phase | Phase 3 |
What the finished NCT00171769 record still lists
NCT00171769 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (74% lower).
The record links to 1 condition, with Persistent Nonvalvular Atrial Fibrillation appearing as the primary indexed condition, and to 1 intervention - of which Certoparin is the first listed.
NCT00171769 reports a single indexed study location in New Jersey, Other.
Frequently Asked Questions
What is clinical trial NCT00171769 about?
NCT00171769 is a clinical study titled "Atrial Fibrillation Feasibility Certoparin Trial - AFFECT". This trial is designed to provide data about feasibility and safety of short-term treatment with the low-molecular-weight heparin certoparin in patients with persistent nonvalvular atrial fibrillation
What is the current status of trial NCT00171769?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 200 participants. The study started on 2005-04.
What conditions does trial NCT00171769 study?
This clinical trial studies the following conditions: Persistent Nonvalvular Atrial Fibrillation.
What interventions are being tested in trial NCT00171769?
The interventions under investigation include: Certoparin (DRUG).
Who is sponsoring clinical trial NCT00171769?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00171769 being conducted?
This trial has 2 study locations across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00171769's enrollment target sits among peer trials
200 1353rd of 2000 higher than 613 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia